Gurnet Point-backed Boston Pharmaceuticals supercharges pipeline with twin deals grabbing top cast-offs from GSK, Novartis
The executive crew at Boston Pharmaceuticals has been busy.
In one 48-hour stretch they completed two big in-licensing deals with a pair of the world’s pharma giants — Novartis and GSK — which will double the size of their clinical pipeline with 4 new therapies and a slate of late-preclinical efforts that should bring the total number of programs in human trials to a dozen by the end of next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
